GSK PLC Overview
Industry: Drug Manufacturers General
Sector: Healthcare
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom. GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vacci Read MoreMavefund brings filings, fundamentals, valuation, price history and news for GSK PLC into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval
Headline from Yahoo Finance: GSK (LSE:GSK) Stock Still Looks Undervalued As Jideytro Wins FDA Approval.
GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval
Headline from Yahoo Finance: GSK (LSE:GSK) Could Be 10% Undervalued On Jideytro FDA Approval.
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
Headline from Yahoo Finance: GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC.
FDA approves GSK’s Jideytro for ROS1-positive lung cancer By Investing.com
Headline from Investing.com Nigeria: FDA approves GSK’s Jideytro for ROS1-positive lung cancer By Investing.com.
GSK wins FDA approval for lung cancer drug Jideytro By Investing.com
Headline from Investing.com Nigeria: GSK wins FDA approval for lung cancer drug Jideytro By Investing.com.
GSK wins FDA approval for lung cancer drug Jideytro
Headline from Investing.com: GSK wins FDA approval for lung cancer drug Jideytro.
Earnings Per Share
Score 2.00/5
GSK PLC earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Drug Manufacturers General industry
, Merck & Company Inc
, Eli Lilly and Company
, Amgen Inc
are companies with high ratings.
Return on Equity
Score 1.96/5
GSK PLC exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.21/5
GSK PLC
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.24/5
GSK PLC
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios